Nuvation Bio Inc reports results for the quarter ended in September - Earnings Summary

Nuvation Bio

02/11/2023 22:18

* Nuvation Bio Inc  NUVB.N  reported a quarterly adjusted
loss
of 9 cents​​ per share for the quarter ended in September,
higher than the same quarter last year, when the company
reported EPS of -12 cents.  The mean expectation of six analysts
for the quarter was for a loss of 11 cents per share. Wall
Street expected results to range from -13 cents to -10 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * Nuvation Bio Inc's reported EPS for the quarter was a loss
of 9
cents​.
    * The company reported a quarterly loss of $19.65 million.
    * Nuvation Bio Inc shares had fallen by 13.4% this
quarter and
lost 39.6% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 3.7%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Nuvation Bio Inc
is $4.75 
This summary was machine generated from LSEG data November 2 at
10:17 p.m. UTC. ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2023      -0.11          -0.09          Beat
 Jun. 30 2023      -0.11          -0.09          Beat
 Mar. 31 2023      -0.10          -0.10          Met
 Dec. 31 2022      -0.11          -0.10          Beat